Elicera Therapeutics: Tackling Tumour Heterogeneity - Redeye

Redeye initiates coverage of Elicera Therapeutics, a Swedish clinical-stage biotech company focusing on cell and gene therapies for cancer treatment. Thanks to its promising focus on CAR-T – a modality we find highly promising – and its iTANK platform, aiming to broaden the use of CAR-T to solid tumours, we see good prospects for Elicera if it can demonstrate positive clinical results, potentially as early as next year.

Länk till analysen i sin helhet: https://www.redeye.se/research/1043919/elicera-therapeutics-tackling-tumour-heterogeneity?utm_source=finwire&utm_medium=RSS